IMR Press / FBL / Special Issues / neuroendocrine_carcinoma

Advances in Neuroendocrine Carcinoma Research

Submission deadline: 01 October 2022
Special Issue Editor
  • Sazan Rasul, PhD
    Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
    Interests: Prostate cancer; Breast cancer; Neuro-endocrine tumor/carcinoma
Special Issue Information

Dear Colleagues,

Neuroendocrine tumors (NETs) are a group of tumors that originate from cells of the endocrine and nervous systems. They are characterized by the secretion of various amines and polypeptide hormones that are responsible for the clinical symptoms of this disease. Although NETs arise most commonly in the intestine, pancreas and lungs, other organs such as the pituitary and thyroid, breast, uterus, prostate and colon may also be affected. Based on the features of tumor grade and histological cell proliferation using the Ki-67 index, the World Health Organization has classified NETs into three main categories: well-differentiated NETs with benign, uncertain behavior; well-differentiated NETs with low-grade malignant behavior; and poorly differentiated NETs or carcinomas. While most NETs are sporadic, they can also occur as part of several inherited familial syndromes such as multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2).

There have been intensive studies of the hormones secreted by NETs, as well as potential markers such as chromogranin A, urine 5-hydroxyindoleacetic acid, neuron-specific enolase, synaptophysin, N-terminally truncated variant of Hsp70, CDX2, and neuroendocrine secretory protein-55. The diagnostic and treatment options of NETs patients have been dramatically improved by morphological imaging with computed tomography scans, magnetic resonance imaging, sonography and endoscopy, molecular imaging using Gallium-68 positron emission tomography/computed tomography (PET/CT), and OctreoScan targeting somatostatin receptors which are highly expressed in NETs. PET using fluorine-18 fluorodeoxyglucose also plays a crucial role in visualizing NETs that grow more aggressively and exhibit increased glycolytic metabolism.

For this special issue, I look forward to receiving your valuable experimental, preclinical and clinical contributions that reflect your highly regarded experience in the field of NETs and neuroendocrine carcinoma.

Dr. Sazan Rasul

Guest Editor

Keywords
Neuroendocrine tumors
Neuroendocrine carcinoma
PET imaging
Theranostics
immunohistochemistry
Somatostatin receptors
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top